Sandoz Group AG Revenue

Sandoz Group AG had revenue of $5.27B in the half year ending June 30, 2025, with 6.80% growth. This brings the company's revenue in the last twelve months to $10.59B, up 4.71% year-over-year. In the year 2024, Sandoz Group AG had annual revenue of $10.38B with 4.06% growth.

Revenue (ttm)

10.59B

Revenue Growth

+4.71%

P/S Ratio

2.87

Revenue / Employee

529.35K

Employees

22,049

Market Cap

30.39B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	10.38B	405.00M	4.06%
Dec 31, 2023	9.98B	673.00M	7.23%
Dec 31, 2022	9.31B	-372.00M	-3.84%
Dec 31, 2021	9.68B	20.00M	0.21%
Dec 31, 2020	9.66B	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
American Oncology Network	1.76B
Veradigm	588.02M
Glass House Brands	196.17M
Global Cord Blood	196.10M
Elite Pharmaceuticals	122.89M
Mid-Atlantic Home Health Network	27.00M
Silence Therapeutics	25.83M
Northwest Biotherapeutics	937.00K

Revenue Rankings

Sandoz Group AG News

14 hours ago - Sandoz Launches Wyost And Jubbonti In Europe - Nasdaq
14 days ago - Sandoz Announces Launch Of TYRUKO In The US - Nasdaq
14 days ago - James M. O'Brien Appointed Chief Financial Officer at Mesoblast - Benzinga
19 days ago - Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2 - Reuters
19 days ago - EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A - PRNewsWire
26 days ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire
26 days ago - Sandoz To Acquire Just-Evotec Biologics EU SAS In Strategic Biosimilars Expansion Deal - Nasdaq
26 days ago - Evotec (EVO) Sells Biologics Site to Sandoz for $350M - GuruFocus

More News